SMC approves use of HIV treatment drug Dovato

17 September 2019

Article: 53/3705

The Scottish Medicines Consortium (SMC) has approved the use of dolutegravir/lamivudine (Dovato®) within NHSScotland for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents above 12 years of age weighing at least 40kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine. The decision means that patients for whom this two-drug combination is appropriate can be treated with a daily, single-tablet combination of the drugs, as opposed to the currently used three-drug regimens, which gives the same outcome at no additional cost.

Source: SMC, 9 September 2019